Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
Phase III for recurrent/metastatic HPV-negative head and neck cancer, using a 1,500 mg pivotal dose with ORR as a potential accelerated approval endpoint and top-line data expected in mid-2027 (trial ~600–650 patients; ORR analysis triggered at ~350 patients with blinded OS follow-up). Clinical data reported deep, durable activity: the 1,500 mg dose showed a 21% complete response rate and a 55% confirmed response rate with a 21.7-month median duration of response in HPV-negative patients, which Bicara contrasted favorably versus pembrolizumab monotherapy. Bicara's TGF-beta “trap” uses a TGFBR2-based design to preferentially target TGF-beta1/3 and mitigate prior TGF-beta toxicities, and the company recently raised $172 million to support U.S. commercial buildout, parallel randomized studies, and further indication expansion. Interested in Bicara Therapeutics Inc.? Here are five stocks we like better. Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional a
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
BCAX
Earnings
- 11/10/25 - Miss
BCAX
Sec Filings
- 3/11/26 - Form 4
- 3/9/26 - Form 144
- 3/6/26 - Form 4
- BCAX's page on the SEC website